Potential drug-drug interactions related with repurposed drugs for COVID-19

Since the outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak, existing molecules with some evidence in reducing the spread of the virus or to combat symptoms of this worldwide viral disease have been investigated. Drugs have been proposed to reduce viral load, virus entry into the host cell, inflammatory events, pulmonary edema or other signals and symptoms in patients with Covid-19. Two or more drugs are usually employed in therapies and a new circumstance, as Covid-19, increases the risk of more drugs to be prescribed for the patient. Thus, this work aimed to review the main drug interactions involving some repositioned drugs in Brazil for the treatment of Covid-19. We described moderate or severe risk interactions involving non-steroidal anti-inflammatory drugs, azithromycin, dexamethasone, dexchlorpheniramine, hydroxychloroquine, ivermectin and nitazoxanide. This review can support healthcare professionals at decisions about the pharmacotherapeutic strategies used in each patient with Covid-19. Keywords: drug interactions. Covid-19. SARS-CoV-2. Coronavirus.